Labeler
Fresenius Kabi USA, LLC NDC Codes
Fresenius Kabi USA, LLC lists 714 finished drug products in the FDA NDC Directory under NDC labeler codes 63323, 65219, 76045.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Tyenne, Rocuronium, Sodium chloride, Dextrose, Otulfi, ketamine hydrochloride, Sterile Water, Levetiracetam, Cyclophosphamide, Vitalipid N, Ustekinumab-Aauz, Sodium Bicarbonate, ephedrine sulfate, Bomyntra, Succinylcholine Chloride
- Active ingredients
- Tocilizumab, Ustekinumab, Rocuronium bromide, Sodium chloride, Dextrose monohydrate, Phytonadione, Ketamine hydrochloride, Water, Levetiracetam, Denosumab, Cyclophosphamide, Vitamin a palmitate
- NDC labeler codes
- 63323, 65219, 76045
- Strengths (from the 100 most recently listed products)
- Rocuronium bromide 10 mg/mL; Dextrose monohydrate 50 mg/mL; Tocilizumab 162 mg/.9mL; Water 1 mL/mL; Sodium chloride .9 g/100mL; Ustekinumab 45 mg/.5mL; Ustekinumab 90 mg/mL; Ephedrine sulfate 5 mg/mL; Denosumab 70 mg/mL; Succinylcholine chloride dihydrate 20 mg/mL; Diphenhydramine hydrochloride 50 mg/mL; Amiodarone hydrochloride 50 mg/mL; Epinephrine 1 mg/mL; Chlorpromazine hydrochloride 25 mg/mL; Acyclovir sodium 50 mg/mL; Lorazepam 2 mg/mL; Gadobutrol 604.72 mg/mL; Desmopressin acetate 4 ug/mL; Vitamin a palmitate 230 [iU]/mL; Ergocalciferol 40 [iU]/mL
- Dosage forms
- Injection, Solution, Injection, Injection, Solution, Concentrate, Kit, Injection, Powder, For solution, Emulsion, Injection, Emulsion, Injection, Powder, Lyophilized, For solution, Solution
- Routes
- Intravenous, Subcutaneous, Intramuscular, Irrigation, Oral, Epidural, Infiltration, Perineural, Intraocular
- Drug classes (FDA established)
- Osmotic Laxative, Interleukin-6 Receptor Antagonist, Interleukin-12 Antagonist, Interleukin-23 Antagonist, Potassium Salt, Nondepolarizing Neuromuscular Blocker, General Anesthetic, alpha-Adrenergic Agonist, beta-Adrenergic Agonist, Vitamin K, Warfarin Reversal Agent, RANK Ligand Inhibitor, Benzodiazepine, Provitamin D2 Compound, Vitamin A, Norepinephrine Releasing Agent, Depolarizing Neuromuscular Blocker, Histamine-1 Receptor Antagonist, Antiarrhythmic, Catecholamine, Phenothiazine, Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor, Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor, Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor, Opioid Antagonist, Gadolinium-based Contrast Agent, Factor VIII Activator, Vasopressin Analog, alpha-1 Adrenergic Agonist, Vitamin C, Paramagnetic Contrast Agent, Lipoglycopeptide Antibacterial, Heparin Reversal Agent, beta-Adrenergic Blocker, Amide Local Anesthetic, Calcitonin, Antifibrinolytic Agent, Calcium Channel Blocker, Dihydropyridine Calcium Channel Blocker, Proton Pump Inhibitor, Oxytocic, Corticosteroid, Anticholinergic
- HCPCS / J-code
- J3357 — Injection, ustekinumab, for subcutaneous injection, 1 mg, J0897 — Injection, denosumab, 1 mg, J0171 — Injection, adrenalin, epinephrine, 0.1 mg
- Package NDCs
- 108 (from the 100 most recently listed products)
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Potassium Acetate | Potassium acetate 196 mg/mL | Injection, Solution, ConcentrateIntravenous | 65219-512 | 65219-0512-50 | — |
| Verapamil Hydrochloride | Verapamil hydrochloride 2.5 mg/mL | InjectionIntravenous | 65219-384 | 65219-0384-02 | — |
| Epinephrine | Epinephrine 1 mg/mL | Injection, Solution, ConcentrateIntramuscular, Intraocular, Intravenous, Subcutaneous | 63323-696 | 63323-0696-25 | J0171 |
| Nicardipine Hydrochloride | Nicardipine hydrochloride 25 mg/10mL | InjectionIntravenous | 65219-818 | 65219-0818-1065219-0818-13 | — |
| Pantoprazole Sodium | Pantoprazole sodium 40 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | 65219-385 | 65219-0385-10 | — |
| cetrorelix acetate | — | Kit | 65219-292 | 65219-0292-77 | — |
| Dextrosedextrose monohydrate | Dextrose monohydrate 50 mg/mL | Injection, SolutionIntravenous | 65219-456 | 65219-0456-60 | — |
| Dextrosedextrose monohydrate | Dextrose monohydrate 50 mg/mL | Injection, SolutionIntravenous | 65219-458 | 65219-0458-30 | — |
| Dextrosedextrose monohydrate | Dextrose monohydrate 50 mg/mL | Injection, SolutionIntravenous | 65219-460 | 65219-0460-20 | — |
| Dextrosedextrose monohydrate | Dextrose monohydrate 50 mg/mL | Injection, SolutionIntravenous | 65219-462 | 65219-0462-10 | — |
| Dextrosedextrose monohydrate | Dextrose monohydrate 50 mg/mL | Injection, SolutionIntravenous | 65219-464 | 65219-0464-50 | — |
| Tyennetocilizumab-aazg | Tocilizumab 162 mg/.9mL | Injection, SolutionSubcutaneous | 65219-584 | 65219-0584-01 | — |
| Tyennetocilizumab-aazg | Tocilizumab 162 mg/.9mL | Injection, SolutionSubcutaneous | 65219-586 | 65219-0586-04 | — |
| Adalimumab-aacfadalimumab | — | KitSubcutaneous | 65219-620 | 65219-0620-20 | — |
| Oxytocin | Oxytocin 10 [USP'U]/mL | Injection, SolutionIntramuscular, Intravenous | 65219-021 | 65219-0021-01 | — |
| Tyennetocilizumab-aazg | Tocilizumab 80 mg/4mL | Injection, Solution, ConcentrateIntravenous | 65219-590 | 65219-0590-04 | — |
| Tyennetocilizumab-aazg | Tocilizumab 200 mg/10mL | Injection, Solution, ConcentrateIntravenous | 65219-592 | 65219-0592-10 | — |
| Tyennetocilizumab-aazg | Tocilizumab 400 mg/20mL | Injection, Solution, ConcentrateIntravenous | 65219-594 | 65219-0594-20 | — |
| Naloxone Hydrochloride | Naloxone hydrochloride 1 mg/mL | Injection, SolutionIntramuscular, Intravenous, Subcutaneous | 76045-112 | 76045-0112-20 | — |
| Naloxone Hydrochloride | Naloxone hydrochloride .4 mg/mL | Injection, SolutionIntramuscular, Intravenous, Subcutaneous | 76045-114 | 76045-0114-10 | — |
| Otulfiustekinumab-aauz | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | 65219-824 | 65219-0824-01 | J3357 |
| Otulfiustekinumab-aauz | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | 65219-826 | 65219-0826-26 | J3357 |
| Otulfiustekinumab-aauz | Ustekinumab 130 mg/26mL | SolutionIntravenous | 65219-828 | 65219-0828-05 | — |
| Dexamethasone Sodium Phosphate | Dexamethasone sodium phosphate 10 mg/mL | Injection, EmulsionIntramuscular, Intravenous | 76045-212 | 76045-0212-10 | — |
| Glycopyrrolate | Glycopyrrolate .2 mg/mL | Injection, SolutionIntramuscular, Intravenous | 65219-801 | 65219-0801-01 | — |
| Adalimumab-aacfadalimumab | — | KitSubcutaneous | 65219-612 | 65219-0612-6965219-0612-8965219-0612-99 | — |
| Cyclophosphamide | Cyclophosphamide 1 g/50mL | Injection, Powder, For solutionIntravenous, Oral | 65219-131 | 65219-0131-20 | — |
| Cyclophosphamide | Cyclophosphamide 2 g/100mL | Injection, Powder, For solutionIntravenous, Oral | 65219-133 | 65219-0133-20 | — |
| Cyclophosphamide | Cyclophosphamide 500 mg/25mL | Injection, Powder, For solutionIntravenous, Oral | 65219-135 | 65219-0135-20 | — |
| Rocuroniumrocuronium bromide | Rocuronium bromide 10 mg/mL | Injection, SolutionIntravenous | 65219-442 | 65219-0442-05 | — |
| Rocuroniumrocuronium bromide | Rocuronium bromide 10 mg/mL | Injection, SolutionIntravenous | 65219-444 | 65219-0444-10 | — |
| Rocuroniumrocuronium bromide | Rocuronium bromide 10 mg/mL | Injection, SolutionIntravenous | 76045-220 | 76045-0220-50 | — |
| Rocuroniumrocuronium bromide | Rocuronium bromide 10 mg/mL | Injection, SolutionIntravenous | 76045-221 | 76045-0221-50 | — |
| Rocuroniumrocuronium bromide | Rocuronium bromide 10 mg/mL | Injection, SolutionIntravenous | 65219-695 | 65219-0695-05 | — |
| Rocuroniumrocuronium bromide | Rocuronium bromide 10 mg/mL | Injection, SolutionIntravenous | 65219-697 | 65219-0697-10 | — |
| Gadobutrol | Gadobutrol 604.72 mg/mL | InjectionIntravenous | 65219-287 | 65219-0287-30 | — |
| Gadobutrol | Gadobutrol 604.72 mg/mL | InjectionIntravenous | 65219-289 | 65219-0289-65 | — |
| Etomidate | Etomidate 2 mg/mL | Injection, SolutionIntravenous | 65219-445 | 65219-0445-22 | — |
| Desmopressin Acetate | Desmopressin acetate 4 ug/mL | Injection, SolutionIntravenous, Subcutaneous | 65219-293 | 65219-0293-01 | — |
| Desmopressin Acetate | Desmopressin acetate 4 ug/mL | Injection, SolutionIntravenous, Subcutaneous | 65219-295 | 65219-0295-10 | — |
| Vitalipid Nvitamin a palmitate, ergocalciferol, .alpha.-tocopherol, dl-, phytonadione | Vitamin a palmitate 330 [iU]/mL + 3 more ingredients | EmulsionIntravenous | 65219-335 | 65219-0335-82 | — |
| Vitalipid Nvitamin a palmitate, ergocalciferol, .alpha.-tocopherol, dl-, phytonadione | Vitamin a palmitate 230 [iU]/mL + 3 more ingredients | EmulsionIntravenous | 65219-337 | 65219-0337-62 | — |
| Vitalipid Nvitamin a palmitate, ergocalciferol, .alpha.-tocopherol, dl-, phytonadione | Vitamin a palmitate 230 [iU]/mL + 3 more ingredients | EmulsionIntravenous | 65219-339 | 65219-0339-64 | — |
| Sodium Chloride | Sodium chloride 4 meq/mL | Injection, Solution, ConcentrateIntravenous | 63323-099 | 63323-0099-63 | — |
| ketamine hydrochloride | Ketamine hydrochloride 10 mg/mL | InjectionIntramuscular, Intravenous | 65219-184 | 65219-0184-20 | — |
| ketamine hydrochloride | Ketamine hydrochloride 100 mg/mL | InjectionIntramuscular, Intravenous | 65219-186 | 65219-0186-05 | — |
| ketamine hydrochloride | Ketamine hydrochloride 100 mg/mL | InjectionIntramuscular, Intravenous | 65219-186 | 65219-0186-23 | — |
| ketamine hydrochloride | Ketamine hydrochloride 50 mg/mL | InjectionIntramuscular, Intravenous | 65219-188 | 65219-0188-10 | — |
| Idacioadalimumab-aacf | — | KitSubcutaneous | 65219-554 | 65219-0554-2865219-0554-38 | — |
| Sodium chloride | Sodium chloride 9 mg/mL | Injection, SolutionIntravenous | 65219-282 | 65219-0282-10 | — |
Fresenius Kabi USA, LLC: common questions
- What is Fresenius Kabi USA, LLC's NDC labeler code?
- 63323, 65219, 76045. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Fresenius Kabi USA, LLC?
- Med-Code's HCPCS directory matches J3357, J0897, J0171 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.